Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 1 of 116

  1. 000434

    Ferring Pharmaceuticals

    High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ(CIS) with or without papillary tumours

    phase 3 small molecule active

    1 trial

  2. 115747

    Disc Medicine

    Metastatic renal cell carcinoma

    phase 3 small molecule active

    1 trial

  3. 131I-apamistamab

    Actinium Pharmaceuticals

    Acute Leukemia

    phase 3 small molecule active

    1 trial

  4. 1403-0008

    Boehringer Ingelheim

    Advanced dedifferentiated liposarcoma

    phase 3 small molecule active

    1 trial

  5. 1403-0019

    Boehringer Ingelheim

    dedifferentiated liposarcoma

    phase 3 small molecule active

    1 trial

  6. 1407-GUCG

    Ningbo Cancer Hospital

    Progressive or recurrent germ cell tumor (measurable or non-measurable)

    phase 3 small molecule active

    1 trial

  7. 1414-ROG-GUCG

    Ningbo Cancer Hospital

    very high risk localized or locally advanced prostate cancer

    phase 3 small molecule active

    1 trial

  8. 1438-0011

    Boehringer Ingelheim

    advanced or metastatic extrapulmonary neuroendocrine carcinoma

    phase 3 small molecule active

    1 trial

  9. 1438-0012

    Boehringer Ingelheim

    small cell lung cancer

    phase 3 small molecule active

    1 trial

  10. 14395

    Disc Medicine

    ABC borderline resectable pancreatic cancer

    phase 3 other active

    1 trial

  11. 1479-0008

    Boehringer Ingelheim

    non-squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  12. 1479-0032

    Boehringer Ingelheim

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  13. 17000139BLC3001

    Janssen-Cilag International N.V.

    Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder

    phase 3 small molecule active

    1 trial

  14. 17000139BLC3002

    Janssen-Cilag International N.V.

    High-Risk Non-muscle-invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  15. 17000139BLC3004

    Janssen-Cilag International N.V.

    High-Risk Non-muscle-invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  16. 177Lu-TLX591

    Telix Innovations

    Metastatic Castration-resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  17. 2 cycles induction chemotherapy

    The First People's Hospital of Lianyungang

    Locally Advanced Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  18. 2008-46

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 3 other active

    1 trial

  19. 20170770

    Amgen

    Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

    phase 3 small molecule active

    1 trial

  20. 20190009

    Amgen

    Previously treated locally advanced and unresectable or metastatic non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation

    phase 3 small molecule active

    1 trial

  21. 20190172

    Amgen

    Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  22. 20190360

    Amgen

    Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia in older adults

    phase 3 small molecule active

    1 trial

  23. 20200041

    Amgen

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  24. 2020HXFH037

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  25. 2021/3336

    The George Institute

    Maintenance treatment in metastatic non-squamous lung cancer

    phase 3 other active

    1 trial

  26. 20210081

    Amgen

    Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  27. 20210096

    Amgen

    Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpression

    phase 3 small molecule active

    1 trial

  28. 20210098

    Amgen

    Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression

    phase 3 small molecule active

    1 trial

  29. 2022-009

    Ningbo Cancer Hospital

    metastatic breast cancer

    phase 3 small molecule active

    1 trial

  30. 2023/3764

    The George Institute

    Metastatic renal cell carcinoma (mRCC)

    phase 3 small molecule active

    1 trial

  31. 20230005

    Amgen

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  32. 20230016

    Amgen

    Limited-Stage Small-Cell Lung Cancer (LS SCLC)

    phase 3 small molecule active

    1 trial

  33. 20230127

    Amgen

    Early-stage Non-squamous Non-small Cell Lung Cancer

    phase 3 other active

    1 trial

  34. 20230239

    Amgen

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  35. 20240178

    Amgen

    Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.

    phase 3 small molecule active

    1 trial

  36. 213350/3000-03-005

    TESARO Bio Netherlands B.V.

    Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer

    phase 3 small molecule active

    1 trial

  37. 213400

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  38. 213410

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  39. 213823

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  40. 2215-CL-0201

    Astellas Pharma GmbH

    Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

    phase 3 small molecule active

    1 trial

  41. 221530

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 3 small molecule active

    1 trial

  42. 223674

    GlaxoSmithKline

    Neoplasms, Lung

    phase 3 small molecule active

    1 trial

  43. 22615

    Bayer AG

    Advanced non-small cell lung cancer with HER2 (ERBB2) mutation

    phase 3 small molecule active

    1 trial

  44. 3-dimensional conformal radiation therapy

    United Therapeutics Europe Ltd

    Head and Neck Cancer

    phase 3 other active

    1 trial

  45. 4010-03-001

    TESARO Bio Netherlands B.V.

    Recurrent or primary advanced (Stage III or IV) endometrial cancer

    phase 3 small molecule active

    1 trial

  46. 42756493BLC3001

    Janssen-Cilag International N.V.

    Advanced Urothelial Cancer

    phase 3 small molecule active

    1 trial

  47. 42756493BLC3004

    Janssen-Cilag International N.V.

    FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  48. 42756493BLC3005

    Janssen-Cilag International N.V.

    High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.